FDA-Approved Drugs Show Antiviral Activity Against MERS-CoV

This technology involves the screening of a library of 290 FDA-approved or clinically advanced compounds for their antiviral activity against Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). The screening identified 27 compounds with dual antiviral activity against both viruses, belonging to thirteen different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptors used as antipsychotics.

Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation

The Ribopuromycylation (RPM) technology, developed by Dr. Jon Yewdell and Dr. Alexandre David, offers a powerful and universal method for visualizing and studying protein translation within cells. RPM involves the use of puromycin, a molecule that mimics a tyrosyl-tRNA and terminates translation by becoming covalently incorporated into the nascent protein chain's C-terminus within the ribosome's A site. This technique enables the immobilization of puromycylated nascent protein chains on ribosomes when chain elongation inhibitors like cycloheximide or emetine are utilized.

Hearing Protection Attenuation and Fit Using a Neural Network

This technology includes systems and methods which allow for a determination of the attenuation and fit of a hearing protection device based on images of a user’s ear. This technology can be used in a wide range of industrial and military settings including but not limited to factories, construction sites, mines, mills, airports, railroads, and military combat training environments.

Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection

The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.

Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants

This technology involves the development of lgG1 Fe variants designed to interact more effectively with the neonatal Fc receptor (FcRn) in a pH-dependent manner. By enhancing this interaction, these variants extend the serum half-life of therapeutic antibodies, reducing the need for frequent administration. This breakthrough holds the potential to make therapeutic antibody treatments more convenient, cost-effective, and accessible for a wide range of diseases.

Mass Spectrometry Derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk

This technology includes a combination of protein biomarkers and clinical risk factors to be used as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that can improve the identification of individuals at high risk for atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Incorporation of novel protein biomarkers of ASCVD risk into risk assessment algorithms may improve their ability to identify individuals at high risk for ASCVD.

A Method to Guide Protocol Development for Magnetic Resonance Thermometry

This technology includes tools to guide optimization of thermometry imaging/post-processing protocols. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue.

A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry

This technology includes a novel Principal Component Analysis (PCA) based approach to correct motion related B0 changes in PRF thermometry. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue.